Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward
Highlights • Adjuvant anti-TIGIT plus pembrolizumab shows futility in melanoma.• Combination increases toxicity, including two treatment-related deaths.• Pembrolizumab monotherapy remains standard adjuvant care.• Trial highlights need for active comparators and predictive biomarkers.